enzh-TWfrdeitjaptrues

This is where we will be posting upcoming events of note.  Please return to this page as we intend to update on a regular basis.

Latest Bing Center News

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely — while reaching more people, quickly and cheaply.

Read more..

Current and Future Treatments for Waldenstrom Macroglobulinemia

Current and Future Treatments for Waldenstrom Macroglobulinemia

What are the treatments for Waldenstrom macroglobulinemia and what's in the pipeline? Can Waldenstrom patients plan for a higher quality of life? Dr. Jorge Castillo, Clinical Director, Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, presents an overview of his presentation at the 2020 IWMF with Patient Power co-founder Andrew Schorr.

Read more..

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Workshop Date and Time: Wednesday, April 21, 2021, 12:30 – 1:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast.

Read more..

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou and Meletios A. Dimopoulos present a summary of trial findings and details regarding various BTK inhibitors, including ibrutinib, zanubrutinib, acalabrutinib, tirabrutinib, LOXO-305, etc.

Read more..

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). The Prescription Drug User Fee Act (PDUFA) target action date is October 18, 2021.

Read more..

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

December 21, 2020: Dr. Jorge Castillo walks us through immunology basics, teaches us the limitations of the SPEP, plus some additional tests that complement it (think Immunofixation), shares his clinical gestalt about when to suspect MGUS, Myeloma, Waldenstrom’s, and Amyloidosis–and finally, how to talk to patients about them.

Read more..

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

Dear IMS Member: We hope you are well during these difficult times. As a response to the current pandemic, the International Myeloma Society has developed the following Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance.

Read more..

Cancer and the COVID-19 Vaccine

Cancer and the COVID-19 Vaccine

On January 27, Dana Farber held a webinar to review the information regarding COVID-19 vaccinations for patients. Catherine Flynn (from the Bing Center Clinic) shares the following highlights from the webinar.  Note, the entire webinar was recorded and posted to Facebook, using the following link:

Read more..

COVID-19 Facts and Resources

COVID-19 Facts and Resources

Based on the latest guidance we have received from the state of Massachusetts, we expect Dana-Farber's supply of COVID-19 vaccine for patients to be very limited in February and perhaps longer. We are working hard to place special focus on getting vaccines to our most at-risk patients, in compliance with the state's rollout guidelines, as we receive allotments of the vaccine.

Read more..

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Please join the Center for Multiple Myeloma for a free webinar for patients and families to learn about the most recent updates in muliple myeloma and Waldenstrom's macroglobulinemia including the impact of COVID-19 and vaccination.

Read more..